American Operating Cycle from 2010 to 2026
| AONC Stock | 11.50 0.00 0.00% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 60.76 | Current Value 67.88 | Quarterly Volatility 4.18029917 |
Check American Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among American Oncology's main balance sheet or income statement drivers, such as Net Income Applicable To Common Shares of 2.1 M, Income Tax Expense of 2.7 M or Tax Provision of 3 M, as well as many indicators such as Price To Sales Ratio of 0.0431, Dividend Yield of 0.0 or PTB Ratio of 4.04. American financial statements analysis is a perfect complement when working with American Oncology Valuation or Volatility modules.
American | Operating Cycle | Build AI portfolio with American Stock |
Analyzing American Oncology's Operating Cycle over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Operating Cycle has evolved provides context for assessing American Oncology's current valuation and future prospects.
Latest American Oncology's Operating Cycle Growth Pattern
Below is the plot of the Operating Cycle of American Oncology Network over the last few years. It is American Oncology's Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in American Oncology's overall financial position and show how it may be relating to other accounts over time.
| Operating Cycle | 10 Years Trend |
|
Operating Cycle |
| Timeline |
American Operating Cycle Regression Statistics
| Arithmetic Mean | 66.07 | |
| Geometric Mean | 65.93 | |
| Coefficient Of Variation | 6.33 | |
| Mean Deviation | 2.90 | |
| Median | 67.97 | |
| Standard Deviation | 4.18 | |
| Sample Variance | 17.47 | |
| Range | 15.138 | |
| R-Value | (0.56) | |
| Mean Square Error | 12.81 | |
| R-Squared | 0.31 | |
| Significance | 0.02 | |
| Slope | (0.46) | |
| Total Sum of Squares | 279.60 |
American Operating Cycle History
About American Oncology Financial Statements
American Oncology stakeholders use historical fundamental indicators, such as American Oncology's Operating Cycle, to determine how well the company is positioned to perform in the future. Although American Oncology investors may analyze each financial statement separately, they are all interrelated. For example, changes in American Oncology's assets and liabilities are reflected in the revenues and expenses on American Oncology's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in American Oncology Network. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Operating Cycle | 60.76 | 67.88 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether American Oncology Network offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of American Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of American Oncology Network Stock. Outlined below are crucial reports that will aid in making a well-informed decision on American Oncology Network Stock:Check out the analysis of American Oncology Correlation against competitors. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Will Health Care Providers & Services sector continue expanding? Could American diversify its offerings? Factors like these will boost the valuation of American Oncology. If investors know American will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every American Oncology data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.89) | Revenue Per Share | Quarterly Revenue Growth 0.514 | Return On Assets | Return On Equity |
Understanding American Oncology Network requires distinguishing between market price and book value, where the latter reflects American's accounting equity. The concept of intrinsic value - what American Oncology's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push American Oncology's price substantially above or below its fundamental value.
Understanding that American Oncology's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether American Oncology represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, American Oncology's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.